Omada Health, Inc. 10-Q

Item 1. Financial Statements (unaudited) OMADA HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per-share data, unaudited) March 31, 2026 December 31, 2025 Assets Current assets Cash and cash equivalents $ 211,765 $ 222,036 Accounts receivable, net (1) 39,985 34,585 Inventory 3,831 4,486 Deferred commissions, current 4,019 3,539 Prepaid expenses and other current assets (2) 9,827 8,288 Total current assets 269,427 272,934 Property and equipment, net 8,455 7,942 Deferred commissions, non-current 9,475 8,711 Intangible assets, net 1,975 2,414 Goodwill 13,240 13,240 Other assets 226 165 Total assets $ 302,798 $ 305,406 Liabilities and stockholders’ equity Current liabilities Accounts payable (3) $ 8,100 $ 10,276 Accrued expenses and other current liabilities (4) 31,227 40,392 Deferred revenue (5) 29,353 25,058 Total current liabilities 68,680 75,726 Other liabilities, non-current - - Total liabilities 68,680 75,726 Commitments and contingencies (Note 5) Stockholders’ equity Common stock, $ 0.001 par value per share; 750,000 and 750,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 59,240 and 58,429 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 59 58 Additional paid-in capital 693,773 686,366 Accumulated deficit ( 459,714 ) ( 456,744 ) Total stockholders’ equity 234,118 229,680 Total liabilities and stockholders’ equity $ 302,798 $ 305,406 (1) Includes amounts from a related party of $ 25.8 million and $ 22.8 million as of March 31, 2026 and December 31, 2025, respectively. (2) Includes amounts from a related party of $ 0.5 million and $ 0.3 million as of March 31, 2026 and December 31, 2025, respectively. (3) Includes amounts from a related party of $ 0 and $ 1.0 million as of March 31, 2026 and December 31, 2025, respectively. (4) Includes amounts from a related party of $ 6.9 million and $ 4.9 million as of March 31, 2026 and December 31, 2025, respectively. (5) Includes amounts from a related party of $ 22.2 million and $ 18.8 million as of March 31, 2026 and December 31, 2025, respectively. See accompanying notes to unaudited condensed consolidated financial statements. 3 Table of Contents OMADA HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per-share data, unaudited) Three Months Ended March 31, 2026 2025 Revenue Services (1) $ 69,594 $ 49,496 Hardware (2) 8,454 5,467 Total revenue 78,048 54,963 Cost of revenue Services (3) 14,449 12,744 Hardware 14,906 10,319 Total cost of revenue 29,355 23,063 Gross profit 48,693 31,900 Operating expenses Research and development (4) 12,697 8,806 Sales and marketing (5) 26,787 20,170 General and administrative (6) 13,990 11,320 Total operating expenses 53,474 40,296 Operating loss ( 4,781 ) ( 8,396 ) Other income (expense), net Interest expense ( 18 ) ( 1,074 ) Interest income 1,829 542 Change in fair value of warrant liabilities - ( 520 ) Total other income (expense), net 1,811 ( 1,052 ) Loss before provision for income taxes ( 2,970 ) ( 9,448 ) Provision for income taxes - - Net loss and comprehensive loss $ ( 2,970 ) $ ( 9,448 ) Net loss per share - basic and diluted $ ( 0.05 ) $ ( 1.15 ) Weighted-average shares outstanding - basic and diluted 58,923 8,241 (1) Includes amounts from a related party of $ 46.0 million and $ 29.9 million for the three months ended March 31, 2026 and 2025, respectively. (2) Includes amounts from a related party of $ 5.1 million and $ 3.4 million for the three months ended March 31, 2026 and 2025, respectively. (3) Includes amounts from a related party of $ 1.3 million and $ 1.2 million for the three months ended March 31, 2026 and 2025, respectively. (4) Includes amounts from a related party of $ 0.7 million and $ 0.5 million for the three months ended March 31, 2026 and 2025, respectively. (5) Includes amounts from a related party of $ 8.4 million and $ 5.6 million for the three months ended March 31, 2026 and 2025, respectively. (6) Includes amounts from a related party of $ 0.5 million and $ 0.3 million for the three months ended March 31, 2026 and 2025, respectively. See accompanying notes to unaudited condensed consolidated financial statements. 4 Table of Contents OMADA HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (in thousands, unaudited) Three Months Ended March 31, 2026 Redeemable Convertible Preferred Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders' Equity Shares Amount Shares Amount Balance as of December 31, 2025 - $ - 58,429 $ 58 $ 686,366 $ ( 456,744 ) $ 229,680 Issuance of common stock upon exercise of stock options - - 781 1 3,246 - 3,247 Issuance of common stock upon settlement of restricted stock units, net of shares withheld for employee taxes - - 30 - - - - Taxes paid related to net share settlement of equity awards - - - - ( 127 ) - ( 127 ) Share-based compensation expense - - - - 4,288 - 4,288 Net loss and comprehensive loss - - - - - ( 2,970 ) ( 2,970 ) Balance as of March 31, 2026 - $ - 59,240 $ 59 $ 693,773 $ ( 459,714 ) $ 234,118 Three Months Ended March 31, 2025 Redeemable Convertible Preferred Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders' Deficit Shares Amount Shares Amount Balance as of December 31, 2024 118,219 $ 449,034 8,157 $ 8 $ 59,555 $ ( 443,966 ) $ ( 384,403 ) Issuance of common stock upon exercise of stock options - - 205 - 919 - 919 Share-based compensation expense - - - - 2,883 - 2,883 Net loss and comprehensive loss - - - - - ( 9,448 ) ( 9,448 ) Balance as of March 31, 2025 118,219 $ 449,034 8,362 $ 8 $ 63,357 $ ( 453,414 ) $ ( 390,049 ) See accompanying notes to unaudited condensed consolidated financial statements. 5 Table of Contents OMADA HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited) Three Months Ended March 31, 2026 2025 Operating activities Net loss $ ( 2,970 ) $ ( 9,448 ) Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization 1,508 1,333 Share-based compensation 4,209 2,844 Loss on disposal of property and equipment 2 1 Amortization of debt issuance costs - 109 Non-cash operating lease expense - 189 Change in fair value of warrant liabilities - 520 Provision for credit losses (1) 806 631 Amortization of deferred commissions 958 734 Changes in operating assets and liabilities Accounts receivable (2) ( 6,206 ) ( 6,496 ) Inventory 655 254 Prepaid expenses and other current assets (3) ( 1,539 ) ( 595 ) Deferred commissions ( 2,202 ) ( 1,200 ) Other non-current assets ( 61 ) 54 Accounts payable (4) ( 2,124 ) 283 Operating lease liabilities - ( 206 ) Accrued expenses and other current liabilities (5) ( 9,165 ) ( 8,425 ) Deferred revenue (6) 4,295 3,256 Other non-current liabilities - 44 Net cash used in operating activities ( 11,834 ) ( 16,118 ) Investing activities Purchases of property and equipment ( 78 ) ( 315 ) Capitalized internal-use software costs ( 1,479 ) ( 934 ) Net cash used in investing activities ( 1,557 ) ( 1,249 ) Financing activities Proceeds from exercise of stock options 3,247 919 Taxes paid related to net share settlement of equity awards ( 127 ) - Payment of deferred offering costs - ( 547 ) Net cash provided by financing activities 3,120 372 Net decrease in cash and cash equivalents ( 10,271 ) ( 16,995 ) Cash and cash equivalents at beginning of period 222,036 76,392 Cash and cash equivalents at end of period $ 211,765 $ 59,397 (1) Includes changes in related party balances of less than $ 0.1 million and $ 0.1 million for the three months ended March 31, 2026 and 2025, respectively. (2) Includes changes in related party balances of $ 3.0 million and $ 4.2 million for the three months ended March 31, 2026 and 2025, respectively. (3) Includes changes in related party balances of $ 0.1 million and $ 0 for the three months ended March 31, 2026 and 2025, respectively. (4) Includes changes in related party balances of $ 1.0 million and $ 0 for the three months ended March 31, 2026 and 2025, respectively. (5) Includes changes in related party balances of $ 2.0 million and $ 1.2 million for the three months ended March 31, 2026 and 2025, respectively. (6) Includes changes in related party balances of $ 3.4 million and $ 3.5 million for the three months ended March 31, 2026 and 2025, respectively. See accompanying notes to unaudited condensed consolidated financial statements. 6 Table of Contents OMADA HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited) Three Months Ended March 31, 2026 2025 Supplemental disclosure of cash flow information Cash paid during the period for: Interest $ 18 $ 896 Supplemental disclosure of noncash investing and financing activities Share-based compensation expense capitalized in internal-use software $ 79 $ 39 Unpaid deferred offering costs included in accounts payable - 494 Unpaid property and equipment included in accounts payable 13 68 7 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 1. Description of Business Omada Health, Inc. (together with its subsidiary and consolidated professional corporation, the “Company” or “Omada”) offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal (“MSK”) conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in its cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. The Company was incorporated in the State of Delaware in April 2011, and its primary office is located in South San Francisco, California. The Company has a remote-first flexible work policy, which provides support and opportunities for employees to work remotely. 2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of Omada Health, Inc., its subsidiary, Physera, Inc., and a professional corporation, Physera Physical Therapy Group, PC (“PPTG” or the “professional corporation”), which was determined to be a variable interest entity (“VIE”) for which Omada is the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in the opinion of management, all the adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods but are not necessarily indicative of the results expected for the full year or any other period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, the unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 6, 2026. Variable Interest Entity The Company determines at the inception of each arrangement whether an entity in which the Company has made an investment or in which the Company has other variable interests is considered a VIE. The professional corporation is considered a VIE since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it is considered the primary beneficiary, which is described as having both (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE. The condensed consolidated balance sheets as of March 31, 2026 and December 31, 2025 include assets of the consolidated VIE, which can only be used to settle obligations of the VIE, and liabilities of the consolidated VIE. As of March 31, 2026, after the elimination of intercompany transaction balances, assets of the consolidated VIE totaled $ 0.8 million, and liabilities of the consolidated VIE totaled $ 0.2 million. As of December 31, 2025, after the elimination of intercompany transaction balances, assets of the consolidated VIE totaled $ 0.8 million, and liabilities of the consolidated VIE totaled $ 0.2 million. 8 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Reverse Stock Split On May 27, 2025, the Company amended its restated certificate of incorporation, as amended, to effect a reverse stock split of shares of the Company’s common stock on a one-for-three basis (the “Reverse Stock Split”). The common stock warrants and options to purchase common stock were subsequently adjusted as a result of the Reverse Stock Split. All impacted share and per-share information included in these consolidated financial statements and notes thereto have been retroactively adjusted to give effect to the Reverse Stock Split. In connection with the one-for-three reverse split of the Company’s common stock effected on May 27, 2025, the conversion price for each series of the Company’s redeemable convertible preferred stock was adjusted such that each share of redeemable convertible preferred stock became convertible into one-third of a share of the Company’s common stock. Initial Public Offering On June 9, 2025, the Company completed its initial public offering (the “IPO”) of 9,085,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase from the Company 1,185,000 shares of the Company’s common stock, at a price to the public of $ 19.00 per share. The gross proceeds to the Company from the IPO were $ 172.6 million and the net proceeds amounted to $ 151.6 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Immediately prior to the closing of the IPO, each outstanding share of the Company’s Series A, Series B, Series C, Series C-1, Series D, Series D-1, and Series E redeemable convertible preferred stock, including shares of redeemable convertible preferred stock issued upon the exercise of Series B and Series D redeemable convertible preferred stock warrants, converted into one-third of a share of the Company’s common stock (see Note 6 for additional information). Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expense during the reporting period. The Company’s significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, determining standalone selling price for performance obligations in contracts with customers and variable consideration, the period of benefit for deferred commissions, the fair value of common stock warrants, the fair value of redeemable convertible preferred stock warrants, the valuation and assumptions underlying share-based compensation including the per-share fair value of the Company’s common stock prior to the Company’s IPO, the assessment of useful life and recoverability of long-lived assets, the valuation of deferred tax assets, and reserves for uncertain tax positions. By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from those estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies from the audited consolidated financial statements for the fiscal year ended December 31, 2025, included in the Annual Report. Segment and Geographic Information The Company considers operating segments to be components of the Company for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The CODM for the Company is the Chief Executive Officer. The CODM reviews financial information on a consolidated basis to make decisions about how to allocate resources and how to measure the Company’s performance. The Company has determined that it has one operating and reportable segment (refer to Note 9 for additional information). 9 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Concentrations of Credit Risk and Significant Customers and Channel Partners Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable. The Company holds cash at major financial institutions that often exceed Federal Deposit Insurance Corporation insured limits. The Company manages its credit risk associated with cash concentrations by concentrating its cash deposits in high quality financial institutions and by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The carrying value of cash approximates fair value. Historically, the Company has not experienced any losses due to such cash concentrations. Concentrations of credit risk with respect to accounts receivable are primarily limited to certain customers and channel partners to which the Company makes substantial sales. Significant customers and channel partners are those which represent 10% or more of the accounts receivable balance or revenue for the periods presented. Customers and channel partners that accounted for 10% or more of accounts receivable, net as of March 31, 2026 and December 31, 2025, or 10% or more of revenue for the three months ended March 31, 2026 and 2025 were as follows: Accounts Receivable, net Revenue As of Three Months Ended March 31, March 31, 2026 December 31, 2025 2026 2025 Partner A 27 % 21 % 33 % 31 % Partner B 37 % 45 % 33 % 29 % Partner A and Partner B are each affiliates of The Cigna Group (refer to Note 8 for additional information). Fair Value of Financial Instruments Certain financial instruments are required to be recorded at fair value. Other financial instruments, including cash and cash equivalents, are recorded at cost, which approximates fair value. Additionally, the carrying amounts of accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to their short-term nature. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: Level 1 inputs: Quoted prices for identical assets and liabilities in active markets. Level 2 inputs: Assets and liabilities based on observable market data for similar instruments, such as quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data. Level 3 inputs: Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require judgment. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. Contract Assets Contract assets include amounts related to the Company’s enforceable right to consideration for completed performance obligations that cannot be invoiced yet under the terms of the contract. Contract assets relate primarily to hardware revenue that is recognized upon shipment and has not yet been invoiced. The contract assets are reclassified to accounts receivable, net when the rights to payment become unconditional. As of March 31, 2026 and December 31, 2025, the Company had $ 1.4 million and $ 0.6 million short-term contract assets, respectively, included in prepaid expenses and other current assets in the condensed consolidated balance sheets. 10 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Deferred Revenue Deferred revenue consists primarily of payments received and accounts receivable recorded in advance of the delivery or completion of the services. Deferred revenue associated with upfront payments for enrollment is generally recognized over the estimated benefit period to the member of twelve months. As of March 31, 2026 and December 31, 2025, deferred revenue was classified as a current liability based on the anticipated recognition period of twelve months or less. During the three months ended March 31, 2026, the Company recognized revenue of $ 12.9 million that was included in the deferred revenue balance at the beginning of the year. New Accounting Pronouncements Not Yet Adopted In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2024-03, Disaggregation of Income Statement Expenses, which requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statement disclosures. In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) and Website Development Costs (Subtopic 350-50): Modernization of Guidance for Internal-Use Software. The update streamlines the cost-capitalization model for internal-use software by redefining project stages, focusing capitalization on costs incurred after “significant development uncertainty” is resolved, and eliminating the standalone website-development guidance. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027 and interim periods within those annual periods; early adoption is permitted. Entities may apply the guidance prospectively or use a modified transition approach that records a cumulative-effect adjustment at adoption. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statement disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the scope for interim reporting guidance. The amendments in this update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 for public business entities. Early adoption is permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statement disclosures. 3. Fair Value Measurements The following table presents information about the Company’s financial assets measured at fair value on a recurring basis based on the fair value hierarchy as follows (in thousands): As of March 31, 2026 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 196,003 $ - $ - $ 196,003 Total $ 196,003 $ - $ - $ 196,003 As of December 31, 2025 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 206,018 $ - $ - $ 206,018 Total $ 206,018 $ - $ - $ 206,018 11 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Level 3 liabilities that were measured at fair value on a recurring basis consisted of Series B and D redeemable convertible preferred stock warrant liabilities and common stock warrant liabilities associated with warrants issued in connection with the Company’s financing arrangements that were cashless exercised and converted to the Company’s common stock during the year ended December 31, 2025. The Company recognized losses on the changes in the fair value of convertible preferred stock warrants and common stock warrants of $ 0.5 million during the three months ended March 31, 2025. No preferred stock warrant liabilities remained outstanding as of March 31, 2026. The Company recognizes transfers among Level 1, Level 2, and Level 3 classifications as of the actual date of the events or change in circumstances that caused the transfers. There were no transfers between fair value measurement levels during the periods presented. 4. Consolidated Balance Sheet Components Accounts Receivable, Net Accounts receivable, net consists of the following (in thousands): As of March 31, 2026 December 31, 2025 Billed accounts receivable $ 13,604 $ 13,563 Unbilled accounts receivable 27,849 22,182 Allowance for credit losses ( 1,468 ) ( 1,160 ) Total accounts receivable, net $ 39,985 $ 34,585 A roll forward of the Company’s allowance for credit losses is as follows (in thousands): Three Months Ended March 31, 2026 2025 Balance at beginning of period $ ( 1,160 ) $ ( 1,985 ) Provision for credit losses, net ( 806 ) ( 631 ) Other adjustments and write-offs 498 513 Balance at end of period $ ( 1,468 ) $ ( 2,103 ) Inventory Inventory is comprised of finished goods inventory. There was no reserve for excess and obsolete inventory recorded as of March 31, 2026 and December 31, 2025. 5. Commitments and Contingencies Legal Matters From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. The Company is not presently a party to any such litigation the outcome of which, the Company believes, if determined adversely to the Company, would individually, or taken together, have a material adverse effect on the Company’s business, operating results, cash flows, or financial condition. 12 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Indemnification In the ordinary course of business, the Company includes in its agreements indemnification provisions of varying scope and terms pursuant to which it agrees to indemnify customers, channel partners, suppliers, vendors, lessors, business partners, and other parties with respect to certain matters, including, but not limited to, losses arising out of the breach of such agreements, services to be provided by the Company, or from intellectual property infringement claims made by third parties. The term of these indemnification provisions generally survive the termination of the agreements indefinitely. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. No demands have ever been made upon the Company to provide indemnification under such agreements, and there are no claims under those indemnification terms that the Company is aware of that could have a material effect on the condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, or condensed consolidated statements of cash flows. Accordingly, the Company had no liabilities recorded for these provisions as of March 31, 2026 and December 31, 2025. Other Commitments Other contractual commitments primarily consist of technology and cloud services related to the Company’s daily business operations. As of March 31, 2026, future minimum payments under the Company’s non-cancellable purchase commitments, for the years ended December 31, were as follows (in thousands): Remainder of 2026 $ 4,433 2027 3,692 2028 1,778 2029 - 2030 - Thereafter - Total $ 9,903 The purchase obligation amounts do not represent the entire anticipated purchases in the future but represent only those items for which the Company is contractually obligated. The majority of the Company’s goods and services are purchased as needed, with no unconditional commitment. For this reason, these amounts do not provide an indication of the Company’s expected future cash outflows related to purchases. 6. Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) Common and Preferred Stock In connection with the closing of its IPO, on June 9, 2025, the Company’s restated certificate of incorporation was amended and restated to authorize 750,000,000 shares of common stock, par value $ 0.001 per share, and 10,000,000 shares of preferred stock, par value $ 0.001 per share. No shares of preferred stock were outstanding as of March 31, 2026. The total shares of the Company’s common stock reserved for issuance on an as-converted basis are as follows (in thousands): As of March 31, 2026 December 31, 2025 Outstanding RSUs 3,751 928 Common stock options outstanding 10,093 10,874 Common stock shares available for future grants 4,107 3,973 Shares available for purchase under the ESPP 1,706 1,121 Total shares of common stock reserved 19,657 16,896 Redeemable Convertible Preferred Stock The Company previously issued shares of redeemable convertible preferred stock. Immediately prior to the closing of the IPO on June 9, 2025, all 118,218,801 shares of the Company’s Series A, Series B, Series C, Series C-1, Series D, Series D-1, and Series E redeemable convertible preferred stock, excluding shares issued upon the exercise of Series B and Series D convertible redeemable preferred stock warrants disclosed below, converted into an aggregate of 39,406,221 shares of the Company’s common stock (after adjusting the conversion ratios of the redeemable convertible preferred stock to give effect to the Reverse Stock Split), and such shares of redeemable convertible preferred stock were cancelled, retired, and eliminated from the shares of stock that the Company is authorized to issue and shall not be reissued by the Company. Following the IPO and as of March 31, 2026, no shares of redeemable convertible preferred stock were outstanding. Redeemable Convertible Preferred Stock and Common Stock Warrants The Company previously issued common and redeemable convertible preferred stock warrants in connection with certain notes payable and debt financing transactions. Following the closing of our IPO, all outstanding warrants were exercised. As of March 31, 2026 and December 31, 2025, no redeemable convertible preferred stock warrants or common stock warrants were outstanding. As of March 31, 2025, the Company had outstanding warrants to purchase shares of the Company’s common stock and outstanding warrants to purchase shares of the Company’s Series B and Series D redeemable convertible preferred stock that were classified as liabilities. The change in fair value for the three months ended March 31, 2025 resulted in a loss of $ 0.5 million for all three instruments. 7. Share-Based Compensation 2011 Equity Incentive Plan Pursuant to the terms of the 2025 Plan (as defined below), any shares subject to outstanding options originally granted under the Company’s 2011 Equity Incentive Plan (the “2011 Plan”) that terminate, expire, or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2025 Plan. In connection with the effectiveness of the 2025 Plan, the 2011 Plan terminated, and no further awards will be granted under the 2011 Plan. However, all outstanding awards will continue to be governed by their existing terms. 2025 Equity Incentive Plan In connection with the IPO, the Company’s board of directors adopted, and its stockholders approved, the 2025 Incentive Award Plan (the “2025 Plan”), which became effective on the day prior to the effectiveness of the Company’s Registration Statement on Form S-1. Under the 2025 Plan, 5,045,541 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit (“RSU”) awards, and other stock-based awards. The number of shares initially reserved for issuance pursuant to awards under the 2025 Plan will be increased by (i) the number of shares represented by awards outstanding under the 2011 Plan (“Prior Plan Awards”) that become available for issuance under the applicable counting provisions following the effective date of the 2025 Plan and (ii) an annual increase on the first day of each calendar year beginning in calendar year 2026 and ending in calendar year 2035, equal to the lesser of (A) 5 % of the shares of the Company’s common stock outstanding (on an as-converted basis) on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of stock as determined by the Company’s board of directors; provided, however, that no more than 15,136,624 shares of common stock may be issued upon the exercise of incentive stock options (“ISOs”). Terms of stock awards, including vesting requirements, are determined by the Company’s board of directors or by a committee authorized by the Company’s board of directors, subject to provisions of the 2025 Plan. The term of any stock option granted under the 2025 Plan cannot exceed ten years . Generally, awards granted by the Company vest over four years , but may be granted with different vesting terms. In conjunction with the effectiveness of the 2025 Plan, the 2011 Plan terminated, and no further awards will be granted under the 2011 Plan, although all outstanding awards under the 2011 Plan will continue to be governed by their existing terms. As of March 31, 2026 and December 31, 2025, 4,107,292 and 3,973,135 shares were available for future issuance pursuant to the 2025 Plan, respectively. 13 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 2025 Employee Stock Purchase Plan In connection with the IPO, the Company’s board of directors adopted, and its stockholders approved, the 2025 Employee Stock Purchase Plan (the “ESPP”), which became effective on the day prior to the effectiveness of the Company’s Registration Statement on Form S-1, with an initial reserve of 1,121,231 shares of the Company’s common stock. The ESPP allows eligible employees to purchase shares of the Company's common stock at a discount through payroll deductions of up to 15 % of their compensation, subject to plan limitations. Such payroll deductions will be expressed as a whole number percentage, and the accumulated deductions will be applied to the purchase of shares of common stock on each purchase date. However, a participant may not purchase more than 666 shares of common stock in each offering period and may not subscribe for more than $ 25,000 in fair market value of shares of common stock (determined at the time the option is granted) during any calendar year. The ESPP administrator has the authority to change these limitations for any subsequent offering period. Unless otherwise determined by the Company's board of directors, employees are able to purchase shares at 85 % of the lower of the fair market value of the Company's common stock on the first date of an offering or on the purchase date. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. The number of shares of the Company's common stock reserved for issuance under the ESPP will automatically increase on January 1 of each year for a period of ten years , beginning on January 1, 2026 and continuing through December 31, 2035, by the lesser of (i) 1 % of the shares of common stock outstanding (on an as-converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the board of directors; provided, however, no more than 6,727,388 shares of common stock may be issued under the ESPP. The shares reserved for issuance under the ESPP may be authorized but unissued shares or reacquired shares. As of March 31, 2026 and December 31, 2025, 1,706,431 and 1,121,231 shares were available for future issuance pursuant to the ESPP, respectively. As of March 31, 2026 the first offering period under the ESPP had not commenced. Stock-based Compensation Expense A summary of share-based compensation expense recognized in the condensed consolidated statement of operations and comprehensive loss is as follows (in thousands): Three Months Ended March 31, 2026 2025 Services cost of revenue $ 62 $ 38 Research and development 739 495 Sales and marketing 1,438 730 General and administrative 1,970 1,581 Total share-based compensation expense $ 4,209 $ 2,844 As of March 31, 2026, there was approximately $ 15.5 million of total unrecognized compensation costs related to unvested stock options, which is expected to be recognized over the weighted-average period of 2.4 years using the straight-line method. The Company’s RSUs vest based on the terms in the grant agreements and generally vest ratably over a period of between one and four years from the vesting commencement date. A summary of unvested RSUs as of March 31, 2026 is as follows (in thousands, except per-share amounts): 14 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested as of December 31, 2025 925 $ 20.09 Granted 2,955 13.56 Vested ( 40 ) 18.87 Canceled/Forfeited ( 92 ) 15.99 Unvested as of March 31, 2026 3,748 $ 15.04 As of March 31, 2026, there was approximately $ 53.6 million of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 3.8 years. 8. Related Party Commercial Arrangements with Cigna and its Affiliates The Company’s customers, channel partners, and vendors include affiliates of The Cigna Group, which beneficially owns more than 5 % of the Company’s outstanding capital stock through Cigna Ventures, LLC. The Company has entered into agreements with these affiliates that, among other things, provide for the provision of the Company’s programs to eligible individuals covered by these affiliates and, in certain cases, for the provision of services by such affiliates in connection with the administration of the Company’s programs. The Company also has agreements with these affiliates for the provision of certain benefits provided to the Company’s employees. Pursuant to these agreements, in addition to the amounts disclosed in the condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, and condensed consolidated statements of cash flows, affiliates of The Cigna Group made payments to the Company of $ 48.3 million and $ 31.0 million during the three months ended March 31, 2026 and 2025, respectively. Additionally, the Company made payments to affiliates of The Cigna Group of $ 7.9 million and $ 4.8 million during the three months ended March 31, 2026 and 2025, respectively. 9. Segment Reporting The Company has one operating and reportable segment, which includes all virtual care program product offerings. The CODM manages the allocation of resources and assesses performance at the operating segment level. The CODM reviews information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance, and allocating resources. The CODM assesses performance and decides how to allocate resources based on components reported on the condensed consolidated statement of operations including consolidated net loss. The CODM uses net loss to evaluate the return on assets and to determine investment opportunities related to development of new virtual care service offerings, new technologies, and platform enhancements. The CODM also uses net loss to monitor budget versus actual results. 15 Table of Contents OMADA HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) The Company’s segment net loss and significant expenses for the three months ended March 31, 2026 and 2025, consisted of the following (in thousands): Three Months Ended March 31, 2026 2025 Revenue $ 78,048 $ 54,963 Cost of revenue (1) 29,355 23,063 Employee compensation (2) 36,979 28,720 Other segment items (3) 14,684 12,628 Consolidated net loss $ ( 2,970 ) $ ( 9,448 ) (1) Depreciation and amortization included in cost of revenue was $ 1.4 million and $ 1.2 million for the three months ended March 31, 2026 and 2025, respectively. (2) Employee compensation is part of research and development, sales and marketing and general and administrative expenses and includes salaries, share-based compensation expense, sales commissions, employee bonuses, benefits, and other employee related expenses. (3) Other segment items include third-party consulting services and professional services, software and infrastructure, hosting, marketing and advertising, and other income and other expenses. All of the Company’s long-lived assets were located in the U.S., and all revenue was earned in the U.S. as of December 31, 2025 and for the three months ended March 31, 2026 and 2025. 10. Income Taxes The Company’s geographical distribution of its losses before provision for income taxes during each period relates to the U.S. The Company did not record a provision for income tax expense or benefit for the three months ended March 31, 2026 and 2025. 11. Net Loss Per Share Attributable to Common Stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except per-share amounts): Three Months Ended March 31, 2026 2025 Numerator: Net income (loss) attributable to common stockholders $ ( 2,970 ) $ ( 9,448 ) Denominator: Weighted-average number of shares used in computing net income (loss) per share attributable to common stockholders, basic and diluted 58,923 8,241 Net income (loss) per share attributable to common stockholders, basic and diluted $ ( 0.05 ) $ ( 1.15 ) As the Company was in a net loss position for the three months ended March 31, 2026 and 2025, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per-share calculations because they would have been anti-dilutive were as follows (in thousands): Three Months Ended March 31, 2026 2025 Redeemable convertible preferred stock on an as-converted basis - 39,406 Common stock options outstanding 10,093 12,250 RSUs outstanding 3,751 - Redeemable convertible preferred stock warrants on an as-converted basis - 259 Common stock warrants - 43 Total 13,844 51,958 12. Subsequent Events The Company has evaluated subsequent events for recognition and measurement purposes through May 8, 2026, which is the date the condensed consolidated financial statements were available to be issued. 16 Table of Contents